Abstract:Objective: Currently there is no cure for cystic fibrosis (CF) disease and lung is the most affected organ [1Cooney A Gene. 2018 Nov; 9: 538Crossref Scopus (72) Google Scholar]. Gene replacement is a promising strategy to treat this disease. However, the two big challenges that have impeded its success are the absence of: (1) an efficient and safe gene delivery reagent to transfect the target cells, and (2) a stable plasmid that enables high and sustained CF transmembrane conductance regulator (CFTR) expression. Thus, the aim of this work is to develop a non-viral CFTR gene replacement system for lung CF disease to overcome these two challenges. Methods: A cationic highly branched poly(β-amino ester) (HPAE) polymer [2Zhou D Sci Adv. 2016 Jun; 6e160010Google Scholar] with high transfection efficiency was used as a non-viral gene delivery reagent complexed to a CpG-depleted CFTR plasmid with high and sustained CFTR expression and expected lower immune response to transfect CF lung epithelial cells in vitro. Results: By using the HPAE for CFTR gene delivery, similar gene expression and higher cell viability (~98%) than commercial transfection reagents such as Xfect™ (~77%) and Lipofectamine™ 3000 (~51%) were achieved after 48 hours. Moreover, around 2400% and 120% higher CFTR protein levels compared to healthy human lung epithelial cells were obtained after 48 hours and 7 days of transfection in CF lung epithelial cells, respectively. Conclusion: We developed a very promising HPAE/CFTR polyplex system as it is demonstrated that only 6–10% CFTR protein expression of healthy lung epithelial cells is enough to restore the ionic transport in CF lung epithelial cells [3Johnson L Nat Genet. 1992 Sep; 2: 21-25Crossref PubMed Scopus (382) Google Scholar]. In addition, a nebulization system for testing this HPAE/CFTR polyplex system in vivo by inhalation in mice is being currently developed. The expected results could potentially support the future use of this technology as a gene therapy for treating lung cystic fibrosis disease.

A breath of fresh air: targeted non-viral in vivo gene correction in the mammalian lung

Experimental Study of Ex Vivo Liposome-mediated Gene Transfer in Orthotopic Rat Left Lung Transplantation

A Two‐Pronged Pulmonary Gene Delivery Strategy: A Surface‐Modified Fullerene Nanoparticle and a Hypotonic Vehicle

In vivo editing of lung stem cells for durable gene correction in mice

Gene Editing and Genetic Lung Disease. Basic Research Meets Therapeutic Application

A promoterless AAV6.2FF-based lung gene editing platform for the correction of surfactant protein B deficiency

WS17.04 Developing a Non-Viral Gene Therapy Strategy for Treating Lung Cystic Fibrosis Disease

Progress in Respiratory Gene Therapy

Targeted Gene Delivery through the Respiratory System: Rationale for Intratracheal Gene Transfer

In Vivo Genome Editing Partially Restores Alpha1-Antitrypsin in a Murine Model of AAT Deficiency

Delivery of genome-editing biomacromolecules for treatment of lung genetic disorders

Lung SORT LNPs enable precise homology-directed repair mediated CRISPR/Cas genome correction in cystic fibrosis models

Gene editing using CRISPR-Cas9 for the treatment of lung cancer

Targeted Gene Correction Directed by Chimeric RNA/DNA Oligonucleotides

Gene Therapy: Will the Promise of Optimizing Lung Allografts Become Reality?

AAV5 delivery of CRISPR-Cas9 supports effective genome editing in mouse lung airway

Gene editing flows to the lungs

Recent advances in aerosol gene delivery systems using non-viral vectors for lung cancer therapy

A Novel AAV-mediated Gene Delivery System Corrects CFTR Function in Pigs

Applications of CRISPR systems in respiratory health: Entering a new 'red pen' era in genome editing

Creating superior lungs for transplantation with next-generation gene therapy during ex vivo lung perfusion